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Registration of Clinical Trials at ClinicalTrials.gov Background
ClinicalTrials.gov is a databank or registry of federally and privately supported clinical trials conducted in the United States and worldwide. It is managed by the National Library of Medicine within the National Institutes of Health (NIH). ClinicalTrials.gov is the result of a federal law requiring that clinical trials be registered to improve public access to information about clinical research . This guidance document provides information about registration requirements.
Federal (FDA) Requirements
All applicable clinical trials must be registered at ClinicalTrials.gov, regardless of funding source. Applicable drug and device clinical trials are defined as follows: 1 Drugs and Biologics: A controlled clinical investigation, other than a Phase 1 clinical investigation, of a drug or biologic product subject to FDA regulation.
Medical Devices:
A prospective clinical study of health outcomes comparing an intervention with a medical device against a control.
Registration is not required for small trials to determine the feasibility of a device or to test prototype devices where the primary outcome measure relates to feasibility, and not to health outcomes.
ICMJE Requirements
As of 2005, most medical journals, including member publications of the International Committee of Medical Journal Editors (ICMJE), require registry as a condition of publication. Thus, researchers who plan to publish in an ICMJE member journal must meet ICMJE guidelines for clinical trial registration.
For both FDA and ICMJE, purely observational studies (those in which the assignment of the healthrelated intervention is not at the discretion of the investigator) do not require registration.
Frequently Asked Questions
When must applicable clinical trials be registered? Federal regulations require that trials be registered no later than 21 days after enrollment of the first participant. However, researchers should be aware that ICMJE requires registration prior to enrollment of any subjects, and member journals may decline publication articles from studies that were not registered in accordance with this requirement.
Results from applicable clinical trials must be reported to ClinicalTrials.gov no later than 12 months after the primary completion date. The primary completion date is defined as the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome.
Registration requirements apply to all new applicable clinical trials and ongoing trials that were initiated after September 27, 2007.
How are applicable clinical trials registered?
Clinical trials are registered via a web-based protocol registration system. Instructions for completing registration can be found at www.clinicaltrials.gov.
What information must be provided to ClinicalTrials.gov?
Detailed information about submission requirements can be found at www.clinicaltrials.gov. In general, initial registration must include administrative and contact information, start date, recruitment plans, location, and a lay person's description of the study (e.g., purpose, study design, primary and secondary outcome measures, target number of subjects, etc.). Results of the study, information about adverse events, and a description of the quality assurance procedures used throughout the trial must also be provided in accordance with the time frames noted above.
Who is responsible for registration?
Responsibility for registration falls to the individual designated to be the "responsible party." In many cases, the sponsor of the trial is the responsible party. However, the principal investigator is the responsible party in cases where there is no sponsor. Additionally, the sponsor can delegate all registration and reporting responsibilities to the principal investigator under the following conditions:
The trial is initiated by the investigator, The investigator has access to and control over the data from the clinical trial, and The investigator has the right to publish the results of the clinical trial.
For research involving an IND (Investigational New Drug Application) or IDE (Investigational Device Exemption Application) with the FDA, the holder of the IND or IDE is the responsible party unless responsibility has been delegated to the principal investigator.
It is very important for researchers to know who the "responsible party" is, related to these requirements. Substantial penalties (i.e., monetary fines, withholding federal funds, denial of publication in an ICMJE journal, etc.) can be levied against responsible parties for failure to meet these requirements.
Principal investigators who are the responsible party may designate an individual to register the trial and complete registration information. However, it is ultimately the responsibility of the PI to ensure that registration occurs and the information provided is accurate and current.
